STAT+: Pharmalittle: We’re reading about Novo licensing a Chinese obesity pill, Merck pulling an antibiotic
Novo’s agreement with Hengrui Pharma, which struck an even bigger deal with GSK last year, highlights the rapid advances in China’s cutting-edge biotech sector.
← Back to stories
National2 articles from 2 sources across the spectrum· Updated 1d ago
2 across the spectrum · tap a section to jump
How each side is putting it
Left
1 viewpointCenter
1 viewpointSTAT+: Pharmalittle: We’re reading about Novo licensing a Chinese obesity pill, Merck pulling an antibiotic, and more
Right
0 viewpointsNo Right coverage yet.
A blind spot on this side of the story.